Status:
UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
Lead Sponsor:
Peking Union Medical College Hospital
Collaborating Sponsors:
Beijing Tiantan Hospital
Conditions:
Glioma
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This is an open-label brain PET/CT (positron emission tomography/computed tomography) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in glioma patients. A ...
Detailed Description
Integrin αvβ3 is an important member of integrin receptor family and expressed preferentially on various types of tumor cells and the activated endothelial cells of tumor angiogenesis, but not or very...
Eligibility Criteria
Inclusion
- Males and females, ≥18 years old；
- In suspicion of brain glioma on MRI；
- The tumor will be surgically removed and histological diagnosis will be available.
Exclusion
- Females planning to bear a child recently or with childbearing potential；
- Known severe allergy or hypersensitivity to IV radiographic contrast；
- Inability to lie still for the entire imaging time because of cough, pain, etc.
- Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc.
- Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.
Key Trial Info
Start Date :
October 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01801371
Start Date
October 1 2012
End Date
December 1 2017
Last Update
April 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730